Strong investment caps active quarter for Seattle-area companies


Adaptive Biotechnologies’ initial public offering was worth $2.1 billion to investors, according to a calculation from venture capital database PitchBook.

Previous Remitly CEO Matt Oppenheimer answers the call
Next The Great Recession, the great expansion and Colorado retail investment real estate

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *